RT Journal Article T1 Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail A1 Alkhayyat, Shadi Salem A1 Al-kuraishy, Hayder M. A1 Al-Gareeb, Ali I. A1 El-Bouseary, Maisra M. A1 AboKamer, Amal M. A1 Batiha, Gaber El-Saber A1 Simal Gándara, Jesús K1 3209.90 Farmacología Experimental K1 3202 Epidemiología K1 2302 Bioquímica AB Introduction Fenofbrate is an agonist of peroxisome proliferator activated receptor alpha (PPAR-α), that possesses antiinfammatory, antioxidant, and anti-thrombotic properties. Fenofbrate is efective against a variety of viral infections anddiferent infammatory disorders. Therefore, the aim of critical review was to overview the potential role of fenofbrate inthe pathogenesis of SARS-CoV-2 and related complications. Results By destabilizing SARS-CoV-2 spike protein and preventing it from binding angiotensin-converting enzyme 2 (ACE2), a receptor for SARS-CoV-2 entry, fenofbrate can reduce SARS-CoV-2 entry in human cells Fenofbrate also suppresses infammatory signaling pathways, which decreases SARS-CoV-2 infection-related infammatory alterations. In conclusion, fenofbrate anti-infammatory, antioxidant, and antithrombotic capabilities may help to minimize the infammatory and thrombotic consequences associated with SARSCoV-2 infection. Through attenuating the interaction betweenSARS-CoV-2 and ACE2, fenofbrate can directly reduce the risk of SARS-CoV-2 infection.Conclusions As a result, fenofbrate could be a potential treatment approach for COVID-19 control. PB Inflammation Research SN 10233830 YR 2022 FD 2022-08-08 LK http://hdl.handle.net/11093/4640 UL http://hdl.handle.net/11093/4640 LA eng NO Inflammation Research, 71, 1159-1167 (2022) NO Financiado para publicación en acceso aberto: Universidade de Vigo/CISUG DS Investigo RD 14-feb-2025